Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 4/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25033725 | 1.00 | NLRP3 (0.39) | NLRP3POLBL3MBTL1HPGDSMN1; SMN2 | |
| SCHEMBL30770385 | 1.00 | NLRP3 (0.39) | NLRP3POLBL3MBTL1HPGDSMN1; SMN2 | |
| SCHEMBL25033802 | 1.00 | NLRP3 (0.39) | NLRP3POLBL3MBTL1HPGDSMN1; SMN2 | |
| SCHEMBL30244385 | 0.92 | NLRP3 (0.39) | NLRP3POLBL3MBTL1HPGDSMN1; SMN2 | |
| SCHEMBL30244229 | 0.92 | NLRP3 (0.39) | NLRP3POLBL3MBTL1HPGDSMN1; SMN2 | |
| SCHEMBL22012145 | 0.92 | NLRP3 (0.39) | NLRP3POLBL3MBTL1HPGDSMN1; SMN2 | |
| SCHEMBL30770395 | 0.92 | NLRP3 (0.39) | NLRP3POLBL3MBTL1HPGDSMN1; SMN2 | |
| SCHEMBL22002747 | 0.91 | NLRP3 (0.38) | NLRP3POLBL3MBTL1HPGDSMN1; SMN2 | |
| SCHEMBL22002741 | 0.91 | NLRP3 (0.38) | NLRP3POLBL3MBTL1HPGDSMN1; SMN2 | |
| SCHEMBL22012176 | 0.90 | NLRP3 (0.36) | NLRP3POLBL3MBTL1HPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230051589-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-02-16 | — | — | US | disclosed |
| US-20230051589-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-02-16 | — | — | US | disclosed |
| WO-2020102576-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS INFLAMMASOME RESEARCH, INC. (US) | 2020-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230051589-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | NLRP3 2/4885POLB 4639/4885L3MBTL1 4806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.